NDAORALTABLET
Approved
Nov 2002
Lifecycle
LOE Approaching
Competitive Pressure
25/100
Clinical Trials
20
Mechanism of Action
mania, is unclear. However, the efficacy of aripiprazole in the listed indications could be mediated through a combination of partial agonist activity at D 2 and 5-HT 1A receptors and antagonist activity at 5-HT 2A receptors.
Pharmacologic Class:
Atypical Antipsychotic
Indications (1)
Clinical Trials (5)
Aripiprazole Once-Monthly in Hospitalized Patients (INITIATE)
Started Nov 2021
200 enrolled
SchizophreniaSchizo Affective DisorderBipolar I Disorder
Specified Drug-use Survey on Abilify Prolonged Release Aqueous Suspension for IM Injection (Prevention of Relapse of Mood Episodes in BP)
Started Apr 2021
535 enrolled
Bipolar Disorder I
Aripiprazole Lauroxil for Preventing Psychotic Relapse After an Initial Schizophrenia Episode
Started Dec 2019
A Trial of Multiple-doses of Aripiprazole in Adults With Schizophrenia or Bipolar 1 Disorder
Started Aug 2019
266 enrolled
SchizophreniaBipolar I Disorder
A Trial in Adult Participants With Schizophrenia Treated Prospectively for 6-months With Abilify MyCite®
Started Apr 2019
277 enrolled
Schizophrenia
Loss of Exclusivity
LOE Date
Mar 2, 2027
12 months away
Patent Expiry
Mar 2, 2027
Company
Otsuka
Japan - Tokushima